BioSpace News Archive

ReCode Therapeutics today announced that Company management will participate in the following upcoming investor conferences in September 2023.

Thermo Fisher Scientific Inc., the world leader in serving science, and the National Minority Quality Forum, an independent not-for-profit research and education organization, announced a collaboration to help bring clinical research to historically underserved patient populations through NMQF’s Alliance for Representative Clinical Trials.

Nanostics Inc. announced that the College of Physicians and Surgeons of Alberta granted provisional accreditation to Nanostics Clinical Laboratory in Edmonton, Alberta, Canada.

Daiichi Sankyo (TSE: 4568) announced today that the first patient has been dosed in a first-in-human phase 1/2 trial evaluating DS-3939 in patients with several types of advanced solid tumors including non-small cell lung, breast, urothelial, ovarian, biliary tract, and pancreatic cancer.

CUTERA, INC. a global leader in aesthetic and dermatology solutions, announces the launch of Secret DUO, an innovative skin resurfacing and revitalization platform that utilizes dual non-ablative fractional technologies.

Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, announced a series of senior leadership promotions and a new senior appointment, effective immediately.

Rapport Therapeutics, Inc today announced the appointment of Cheryl Gault as Chief Operating Officer and Wendy Young, Ph.D., as a member of its Scientific Advisory Board.

VBI Vaccines Inc. today announced the first patients have been dosed in the randomized, controlled Phase 2b study of VBI’s cancer vaccine immunotherapeutic candidate, VBI-1901, in patients with first recurrent glioblastoma (rGBM).

CRISPR Therapeutics announced that Rodger Novak, M.D., President and Chairman of the Board of CRISPR Therapeutics, has elected to leave CRISPR Therapeutics after nearly a decade of dedicated service to the Company.

Perimeter Medical Imaging AI, Inc. today provided an update on the clinical development of its ongoing clinical trial evaluating the use of Perimeter B-Series OCT combined with its proprietary ImgAssist AI software during breast conservation surgery.